Trending...
- DuoKey to Unveil Encrypted Financial Intelligence Use Case at GISEC Global 2025
- Michelle Kerr Makes Strategic Investment in Summit
- Meditech International Inc. and Los Angeles Rams Continue Strategic Partnership to Enhance Athlete Performance and Recovery
COLUMBUS, Ohio ~ Ajinomoto Co., Inc. and Forge Biologics have announced that they have entered into a definitive agreement for Ajinomoto Co. to acquire Forge in an all-cash deal for $620 million.
Forge is a viral vector and plasmid contract development and manufacturing organization (CDMO) and clinical-stage therapeutics company, enabling access to potentially life-changing gene therapies by bringing them from concept to reality. All development and manufacturing is done at the Hearth, Forge's 200,000 square foot custom-designed cGMP facility in Columbus, Ohio, where the business has over 300 employees.
Timothy J. Miller, Ph.D., CEO, President, and Co-founder of Forge said that "Forge has had remarkable growth since our founding in 2020, and we're excited to join Ajinomoto Co., to continue to expand our global business of helping innovators manufacture much needed genetic medicines".
More on Ohio Pen
Yasuyuki Otake, Corporate Executive, General Manager of Bio-Pharma Services Department of Ajinomoto Co., said that "Forge's unparalleled expertise in gene therapy development and manufacturing will be a transformative addition to our core growth area of Healthcare as part of our ASV Initiatives 2030 Roadmap".
Chris Garabedian, Chairman and CEO of Xontogeny and Chairman of Forge's Board of Directors said that "This is a tremendous step to drive Forge's next phase of growth that will maximize the impact they have on their mission for clients and patients".
The transaction is expected to be completed by the end of the fourth quarter of 2023 subject to customary closing conditions including regulatory approvals. Upon completion, Forge will become a fully consolidated subsidiary of Ajinomoto Co., Inc. Centerview Partners LLC served as lead financial advisor and Ice Miller LLP served as legal advisor to Forge in the transaction while Chardan Capital Markets LLC also provided financial advice.
Forge is a viral vector and plasmid contract development and manufacturing organization (CDMO) and clinical-stage therapeutics company, enabling access to potentially life-changing gene therapies by bringing them from concept to reality. All development and manufacturing is done at the Hearth, Forge's 200,000 square foot custom-designed cGMP facility in Columbus, Ohio, where the business has over 300 employees.
Timothy J. Miller, Ph.D., CEO, President, and Co-founder of Forge said that "Forge has had remarkable growth since our founding in 2020, and we're excited to join Ajinomoto Co., to continue to expand our global business of helping innovators manufacture much needed genetic medicines".
More on Ohio Pen
- Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
- Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
- Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
- KRATON ANNOUNCES DECISION TO EXIT DOVER SITE TO FOCUS ON CORE BUSINESS GROWTH
- Goodyear Completes Sale of Dunlop Brand
Yasuyuki Otake, Corporate Executive, General Manager of Bio-Pharma Services Department of Ajinomoto Co., said that "Forge's unparalleled expertise in gene therapy development and manufacturing will be a transformative addition to our core growth area of Healthcare as part of our ASV Initiatives 2030 Roadmap".
Chris Garabedian, Chairman and CEO of Xontogeny and Chairman of Forge's Board of Directors said that "This is a tremendous step to drive Forge's next phase of growth that will maximize the impact they have on their mission for clients and patients".
The transaction is expected to be completed by the end of the fourth quarter of 2023 subject to customary closing conditions including regulatory approvals. Upon completion, Forge will become a fully consolidated subsidiary of Ajinomoto Co., Inc. Centerview Partners LLC served as lead financial advisor and Ice Miller LLP served as legal advisor to Forge in the transaction while Chardan Capital Markets LLC also provided financial advice.
Filed Under: Business
0 Comments
Latest on Ohio Pen
- Whistleblower Seeks SEC and Shareholder Review of Cogent Communications' 2003 Acquisition of FNSI
- Sanders® Celebrates 150 Years with an Immersive NYC Experience, Food Truck Tour, and Exciting New White Chocolate Caramel Creations
- $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
- SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
- New National Nonprofit Launches to Capture Firsthand Accounts of Adoption Stories
- The Tide Project Opens at Biennale Architettura 2025 in Venice Amplifying Youth Voices
- Wall Street analysts say BTC.XRP.DOGE cloud mining company SIX MINING is expected to achieve a 5-fold increase, allowing users to easily mine BTC
- Gen X Takes The Reins: New Book Guides Caregivers Juggling Parents, Kids, And Grandkids With Humor And Heart
- Fray Fitness Launches Memorial Day Sale and Veteran Organization Giveaway
- ABM for Good™ Launches First Project with Build Change
- ProfiSignal 20 Update Provides Significant Features
- ImagineX, in Collaboration with Qualys, Launches New mROC Services to Transform Enterprise Cyber Risk Management
- Ditch Micromanagement: New Leadership Book for Results-Driven, Accountability-Based Teams
- Jay Tapp was named Managing Director in British Columbia
- Hubei Heavy Equipment Makes a Striking Appearance at CIMT and Competes with International Brands
- 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)
- NASDAQ Uplisting for Higher Market Exposure and Wide Corporate Benefits to AI Boosted Marketing Company On Track Towards $1 Billion Revenue by 2027
- Congressional Men's Health Caucus Shows Bipartisan Consensus and Focus on Prevention, Mental Health, and Closing the Lifespan Gap
- Trailhead Biosystems Secures $20 Million to Drive Innovation and Accelerate Growth
- DuoKey, Axiomtek and Blue Edge Network Partner to Enhance Smart Cities with Privacy-Preserving Urban Safeguarding and Fleet Management